Literature DB >> 31126596

Irreversible Electroporation versus Radiofrequency Ablation: Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma.

Katsutoshi Sugimoto1, Kazuhiro Kakimi2, Hirohito Takeuchi3, Nao Fujieda4, Kazuhiro Saito5, Eiichi Sato6, Kentaro Sakamaki7, Fuminori Moriyasu8, Takao Itoi3.   

Abstract

PURPOSE: Irreversible electroporation (IRE) differs from thermal radiofrequency (RF) ablation, especially in terms of the reparative process in the ablation zone induced. To elucidate this, the systemic immune responses after 2 mechanistically different types of ablation (IRE and RF ablation) were evaluated in patients with hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Twenty-one patients with HCC who underwent either RF ablation (n = 11) or IRE (n = 10) were studied. Peripheral blood samples were collected from all patients at 4 timepoints: before ablation, within 1 hour after ablation, 1 day after ablation, and 4 days after ablation. The phenotypes and functions of immune cells in peripheral blood and serum levels of cytokines and chemokines were monitored and analyzed using the mixed-effects model. Follow-up radiological images were also obtained to assess temporal changes in the ablation zone.
RESULTS: The most significant difference was seen in the levels of macrophage migration inhibitory factor (MIF) in the IRE group compared to the RF ablation group (P = .0011): the serum levels of MIF in the IRE group significantly increased immediately after IRE and then rapidly decreased to the pre-ablation range 1 day after IRE, but, in contrast, no consistent trend was observed in the RF ablation group. The axial diameter (P = .0009) and area (P = .0192) of the ablation zone of IRE were significantly smaller than those of RF ablation 1 year after ablation.
CONCLUSIONS: IRE was found to be associated with a significant early increase in MIF levels, which may facilitate the early reparative process and result in significant shrinkage of the ablation zone.
Copyright © 2019 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31126596     DOI: 10.1016/j.jvir.2019.03.002

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  13 in total

1.  Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis.

Authors:  Pankaj Gupta; Muniraju Maralakunte; Sathya Sagar; Praveen Kumar-M; Harish Bhujade; Sreedhara B Chaluvashetty; Naveen Kalra
Journal:  Eur Radiol       Date:  2021-02-27       Impact factor: 5.315

2.  High-frequency irreversible electroporation brain tumor ablation: exploring the dynamics of cell death and recovery.

Authors:  Kelsey R Murphy; Kenneth N Aycock; Alayna N Hay; John H Rossmeisl; Rafael V Davalos; Nikolaos G Dervisis
Journal:  Bioelectrochemistry       Date:  2021-11-17       Impact factor: 5.373

3.  Ablation Zone Involution of Liver Tumors Is Faster in Patients Treated with Irreversible Electroporation Than Microwave Ablation.

Authors:  Fourat Ridouani; Mario Ghosn; Francois Cornelis; Elena N Petre; Meier Hsu; Chaya S Moskowitz; Peter T Kingham; Stephen B Solomon; Govindarajan Srimathveeravalli
Journal:  Medicina (Kaunas)       Date:  2021-08-26       Impact factor: 2.948

4.  Immunological effect of irreversible electroporation on hepatocellular carcinoma.

Authors:  Xiaoxia Guo; Fang Du; Qin Liu; Yan Guo; Qingbing Wang; Wei Huang; Zhongmin Wang; Xiaoyi Ding; Zhiyuan Wu
Journal:  BMC Cancer       Date:  2021-04-21       Impact factor: 4.430

Review 5.  Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV.

Authors:  Cristina Micali; Ylenia Russotto; Grazia Caci; Manuela Ceccarelli; Andrea Marino; Benedetto Maurizio Celesia; Giovanni Francesco Pellicanò; Giuseppe Nunnari; Emmanuele Venanzi Rullo
Journal:  Infect Dis Rep       Date:  2022-01-07

6.  Intraprocedural Transcatheter Intraarterial Perfusion (TRIP)-MRI for Evaluation of Irreversible Electroporation Therapy Response in a Rabbit Liver Tumor Model.

Authors:  Anna J Shangguan; Kang Zhou; Jia Yang; Aydin Eresen; Bin Wang; Chong Sun; Liang Pan; Su Hu; Ali T Khan; Samdeep K Mouli; Vahid Yaghmai; Zhuoli Zhang
Journal:  Clin Exp Gastroenterol       Date:  2020-11-06

Review 7.  Recent progress in pulsed electric field ablation for liver cancer.

Authors:  Zhen-Guo Liu; Xin-Hua Chen; Zu-Jiang Yu; Jun Lv; Zhi-Gang Ren
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

Review 8.  Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature.

Authors:  Maria Walls; Gerard M Walls; Jacqueline A James; Kyle T Crawford; Hossam Abdulkhalek; Tom B Lynch; Aaron J Peace; Terry E McManus; O Rhun Evans
Journal:  BMC Pulm Med       Date:  2020-08-06       Impact factor: 3.317

9.  Effect of microwave ablation treatment of hepatic malignancies on serum cytokine levels.

Authors:  Jing Zhao; Qiang Li; Merlin Muktiali; Bingjie Ren; Yingxi Hu; Dapeng Li; Zhi Li; Daoming Li; Yufeng Xie; Min Tao; Rongrui Liang
Journal:  BMC Cancer       Date:  2020-08-26       Impact factor: 4.430

Review 10.  Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors.

Authors:  Nana Zhang; Zhuoqun Li; Xuan Han; Ziyu Zhu; Zhujun Li; Yan Zhao; Zhijun Liu; Yi Lv
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.